Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trialResults consistent with ...
MBX Biosciences Inc. MBX on Thursday reported full results from its 12-week Avail Phase 2 trial and new one-year data from an ...
SEATTLE -- Parathyroidectomy helped reverse disrupted levels of inflammatory cytokines and vitamin D metabolites in patients with primary hyperparathyroidism (PHPT), a researcher suggested here. After ...
If calcium is elevated on a metabolic panel (usually done because the patient has hypertension or diabetes mellitus), I typically determine ionized calcium and parathyroid hormone (PTH) levels. If the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results